Indivior PLC (LON:INDV – Get Free Report)’s share price was up 11.9% during trading on Thursday . The stock traded as high as GBX 738 ($9.58) and last traded at GBX 731 ($9.49). Approximately 231,070 shares traded hands during trading, a decline of 82% from the average daily volume of 1,264,178 shares. The stock had previously closed at GBX 653.50 ($8.48).
Analysts Set New Price Targets
Separately, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 1,500 ($19.48) price objective on shares of Indivior in a report on Thursday, September 5th.
View Our Latest Stock Analysis on INDV
Indivior Trading Up 1.2 %
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Articles
- Five stocks we like better than Indivior
- Where to Find Earnings Call Transcripts
- Texas Roadhouse Stock Steering for New Highs This Year
- Health Care Stocks Explained: Why You Might Want to Invest
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Why Invest in High-Yield Dividend Stocks?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.